Nasser Alhajj

Dr. Nasser Alhajj

Waterford Institute of Technology, Waterford, Ireland
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Drug Discovery Today
Verified
Journal Article
Closed access
Nasser AlhajjNasser Alhajj
Nasser Alhajj
NONiall J. O’Reilly
Niall J. O’Reilly
HCHelen Cathcart
Helen Cathcart

11 March 2022 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Nasser AlhajjNasser Alhajj
Nasser Alhajj
NONiall J. O'REilly
Niall J. O'REilly
HCHelen Cathcart
Helen Cathcart

6 April 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
KAKhaled Almansour
Khaled Almansour
RARAISUDDIN ALI
RAISUDDIN ALI
FAFawaz Nasser Alheibshy
Fawaz Nasser Alheibshy
TATariq J. Almutairi
Tariq J. Almutairi
RARakan F. Alshammari
Rakan F. Alshammari
MEMustafa M.A. Elsayed
Mustafa M.A. Elsayed
Nano spray drying has emerged as an outstanding platform for engineering micro- and nanoparticles, with growing applications in various areas of drug delivery. As a new technology involving distinct technical design, parameters of the nano spray drying process are not fully elucidated. In a quality-by-design approach, the aim of the current study was to gain thorough understanding of critical determinants of product characteristics in the Büchi Nano Spray Dryer B-90. Following a factorial experimental design, a series of spray drying experiments were conducted to gain new insights into the influences of the inlet temperature, the spray solvent, and the solute concentration in the spray solution on the yield, the moisture content, and the particle size of the nano spray-dried powder material. Special consideration was given to the potential of using hydroethanolic in comparison with aqueous solvent systems and to particle engineering for pulmonary drug delivery. Lactose and mannitol, widely used as excipients in dry powder inhalation formulations, were used as model materials. Lactose and mannitol are known to spray dry in amorphous and crystalline forms, respectively. The yields of spray drying of lactose and mannitol amounted generally to 71.1 ± 6.6% w/w and 66.1 ± 3.5% w/w, respectively. The spray-dried materials exhibited generally a number-weighted median particle diameter of 1.6 ± 0.2 μm and a volume-weighted median particle diameter of 5.1 ± 1.0 μm. A detailed analysis of the results improved understanding of the interplay between process parameters in the Nano Spray Dryer. The results demonstrate that optimization of spray generation is the key to yield optimization. On the other hand, particle size is determined by the spray mesh pore size and the spray solution degree of saturation. Selection of an appropriate spray solvent and using spray solution additives could optimize spray flow. In parallel, the spray solvent and the solute concentration in the spray solution determine the degree of saturation. Guidance on optimization of particle engineering by nano spray drying is provided.

1 May 2020 in Asian Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
Nasser AlhajjNasser Alhajj
Nasser Alhajj
ZZZabliza Zakaria
Zabliza Zakaria
INIdanawati Naharudin
Idanawati Naharudin
FAFakhrul Ahsan
Fakhrul Ahsan
WLWenji Li
Wenji Li
TWTin Wui Wong
Tin Wui Wong
Chitosan nanoparticles are exhalation prone and agglomerative to pulmonary inhalation. Blending nanoparticles with lactose microparticles (∼5 µm) could mutually reduce their agglomeration through surface adsorption phenomenon. The chitosan nanoparticles of varying size, size distribution, zeta potential, crystallinity, shape and surface roughness were prepared by spray drying technique as a function of chitosan, surfactant and processing conditions. Lactose-polyethylene glycol 3000 (PEG3000) microparticles were similarly prepared. The chitosan nanoparticles, physically blended with fine lactose-PEG3000 microparticles, exhibited a comparable inhalation performance with the commercial dry powder inhaler products (fine particle fraction between 20% and 30%). Cascade impactor analysis indicated that the aerosolization and inhalation performance of chitosan nanoparticles was promoted by their higher zeta potential and circularity, and larger size attributes of which led to reduced inter-nanoparticulate aggregation and favored nanoparticles interacting with lactose-PEG3000 micropaticles that aided their delivery into deep and peripheral lungs.

20 November 2018 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
Nasser AlhajjNasser Alhajj
Nasser Alhajj
CCChin Fei Chee
Chin Fei Chee
TWTin Wui Wong
Tin Wui Wong
NRNoorsaadah Abd Rahman
Noorsaadah Abd Rahman
NKNoor Hayaty Abu Kasim
Noor Hayaty Abu Kasim
PCPaolo Colombo
Paolo Colombo
Introduction: Pulmonary drug delivery is organ-specific and benefits local drug action for lung cancer. The use of nanotechnology and targeting ligand enables cellular-specific drug action. Combination approaches increase therapeutic efficacy and reduce adverse effects of cancer chemotherapeutics that have narrow therapeutic index window and high cytotoxicity levels. The current progress of inhaled cancer chemotherapeutics has not been examined with respect to targeting strategy and clinical application potential. Areas covered: This review examines the state of the art in passive (processing and formulation) and active (targeting ligand and receptor binding) technologies in association with the use of nanocarrier to combat lung cancer. It highlights routes to equip nanocarrier with targeting ligands as a function of the chemistry of participating biomolecules, and challenges in inhalational nanoproduct development and clinical applications. Both research and review articles were examined using the Scopus, Elsevier, Web of Science, Chemical Abstracts, Medline, CASREACT, CHEMCATS and CHEMLIST database with the majority of information retrieved between those of 2000-2018. Expert commentary: The therapeutic efficacy of targeting ligand-decorated nanocarriers needs to be demonstrated in vivo in the form of finished inhalational products. Their inhalation efficiency and medical responses require further examination. Clinical application of inhaled nanocancer chemotherapeutics is premature.

25 November 2023 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
Nasser AlhajjNasser Alhajj
Nasser Alhajj
MYMohd Fakharul Zaman Raja Yahya
Mohd Fakharul Zaman Raja Yahya
NONiall J. O'REilly
Niall J. O'REilly
HCHelen Cathcart
Helen Cathcart
Cystic fibrosis (CF) is an inherited lung disease characterised by the accumulation of thick layers of dried mucus in the lungs which serve as a nidus for chronic infection. Pseudomonas aeruginosa is the predominant cause of chronic lung infection in cystic fibrosis. The dense mucus coupled with biofilm formation hinder antibiotic penetration and prevent them from reaching their target. Mucoactive agents are recommended in the treatment of CF in combination with antibiotics. In spite of the extensive research in developing novel drug combinations for the treatment of lung infection in CF, to our knowledge, there is no study that combines antibiotic, antibiofilm and mucoactive agent in a single inhaled dry powder formulation. In the present study, we investigate the possibility of adding a mucoactive agent to our previously developed ciprofloxacinquercetin (antibiotic-antibiofilm) dry powder for inhalation. Three mucoactive agents, namely mannitol (MAN), N-acetyl-L-cysteine (NAC) and ambroxol hydrochloride (AMB), were investigated for this purpose. The ternary combinations were prepared via spray drying without the addition of excipients. All ternary combinations conserved or improved the antibacterial and biofilm inhibition activities of ciprofloxacin against P. aeruginosa (ATCC 10145). The addition of AMB resulted in an amorphous ternary combination (SD-CQA) with superior physical stability as indicated by DSC and nonambient XRPD. Furthermore, SD-CQA displayed better in vitro aerosolization performance (ED ∼ 71 %; FPF ∼ 49 %) compared to formulations containing MAN and NAC (ED ∼ 64 % and 44 %; FPF ∼ 44 % and 29 %, respectively). In conclusion, a ternary drug combination powder with suitable aerosolization, physical stability and antibacterial/antibiofilm properties was prepared by a single spray drying step.